The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 April 2026•

1 min read

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion for REDEMPLO

Key Facts

1The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of REDEMPLO.

Arrowhead Pharmaceuticals announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of REDEMPLO (plozasiran). The siRNA medicine is designed as an adjunct to diet for reducing triglyceride levels in adult patients suffering from familial chylomicronemia syndrome (FCS). This recommendation is based on clinical efficacy in treating the rare genetic condition characterized by severe hypertriglyceridemia. The positive CHMP opinion serves as a critical regulatory milestone toward full marketing authorization within the European Union. This development strengthens the company's position in the biotechnology sector and provides a significant catalyst for its therapeutic pipeline. Investors often view such regulatory progress as a primary driver for long-term value in biotech equities.